Combination of Cryo‐Shocked M1 Macrophages and Lonidamine Nanodrugs Enables Potent Chemo‐Immunotherapy
Advanced Functional Materials · 2024-01 · 34 (2)
DOI: 10.1002/adfm.202310364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Functional Materials, online erschienen am 28.09.2023. Verfasst von Xueying Shi und 11 weiteren Autor:innen. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Basic Research Program of China, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Therapeutics targeting immune checkpoints have achieved astonishing clinical success in cancer treatment. However, these therapies can hardly adapt to immunologically “cold” tumors featuring insufficient and exhausted tumor‐infiltrating lymphocytes as well as low immunogenicity. Herein, a two‐pronged strategy is presented by combining cryo‐shocked M1 macrophages (CSMs) and CD47‐targeted lonidamine nanodrugs (CLNDN) for reprograming the immunosuppressive tumor microenvironment (TME). CSMs induce durable polarization of tumor‐associated macrophages (TAMs) into the immunostimulatory M1 phenotype through the TLR2/MAPK signaling and also elevate CD47 expression in tumor cells, which in turn facilitates the targeted delivery of CLNDN into tumor cells. CLNDN trigger tumor cell‐specific pyroptosis through the caspase‐3/GSDME pathway and lead to the release of damage‐associated molecular patterns. Consequently, the combination of CSM and CLNDN synergistically boosts immune infiltration and tumor cell immunogenicity within the TME, effectively reverting tumor immunosuppression. This combination achieves potent antitumor effects and induces long‐term immune memory against tumor metastasis and recurrence. This work demonstrates for the first time TAM polarization by using cryo‐shocked macrophages and highlights its coordination with tumor pyroptosis for igniting tumor immunity, opening up a new avenue for robust cancer immunotherapy.
Förderung
- National Basic Research Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Fundamental Research Funds for the Central Universities
- National Postdoctoral Program for Innovative Talents
Zitieren
APA
Shi, X., Xiao, B., Xu, X., Pan, Y., Xiang, J., Shao, S., Zhou, Z., Huang, F., Gao, J., Slater, N. K. H., Shen, Y., & Tang, J. (2024). Combination of Cryo‐Shocked M1 Macrophages and Lonidamine Nanodrugs Enables Potent Chemo‐Immunotherapy. Advanced Functional Materials, 34(2). https://doi.org/10.1002/adfm.202310364
Vancouver
Shi X, Xiao B, Xu X, Pan Y, Xiang J, Shao S, et al. Combination of Cryo‐Shocked M1 Macrophages and Lonidamine Nanodrugs Enables Potent Chemo‐Immunotherapy. Advanced Functional Materials. 2024;34(2). doi:10.1002/adfm.202310364
BibTeX
@article{Shi2024,
author = {Shi, Xueying and Xiao, Bing and Xu, Xiaodan and Pan, Yixuan and Xiang, Jiajia and Shao, Shiqun and Zhou, Zhuxian and Huang, Feihe and Gao, Jianqing and Slater, Nigel K. H. and Shen, Youqing and Tang, Jianbin},
title = {Combination of Cryo‐Shocked M1 Macrophages and Lonidamine Nanodrugs Enables Potent Chemo‐Immunotherapy},
journal = {Advanced Functional Materials},
year = {2024},
volume = {34},
number = {2},
doi = {10.1002/adfm.202310364}
}
EUVIMED